Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Adjuvant Trial in Pancreatic Cancer Comparing 5FU and D-L-Folinic Acid vs. Gemcitabine.

Trial Profile

Phase III Adjuvant Trial in Pancreatic Cancer Comparing 5FU and D-L-Folinic Acid vs. Gemcitabine.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemcitabine (Primary) ; Fluorouracil; Folinic acid
  • Indications Adenocarcinoma; Pancreatic cancer; Periampullary cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ESPAC-3
  • Most Recent Events

    • 10 Apr 2021 Results assessing digital quantification of GATA6 immunohistochemistry association with overall survival and pancreatic adenocarcinoma specimens were obtained from patients enrolled in two clinical studies: ESPAC-3 and ESPAC-4 presented at the 112th Annual Meeting of the American Association for Cancer Research
    • 08 Mar 2018 Results of an analysis assessing the intra-tumoural dihydropyrimidine dehydrogenase expression status in patient population from this trial (n= 238), published in the British Journal of Cancer.
    • 11 Jul 2012 Results published in JAMA: the Journal of the American Medical Association.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top